Core Viewpoint - The company has been focusing on the research and development of small molecule innovative drugs while also establishing a large molecule drug discovery team to enhance its R&D capabilities [1] Group 1: Small Molecule Drug Development - The company has a long-standing commitment to the R&D of small molecule innovative drugs [1] - Efforts are being made to consolidate and enhance the existing small molecule drug development foundation [1] Group 2: Large Molecule Drug Development - In recent years, the company has formed a large molecule drug discovery team and built a large molecule R&D platform [1] - The large molecule team is efficiently advancing multiple early-stage projects, with two products already entering the CMC development stage [1] - The company aims to submit IND applications for these products as soon as possible [1]

据交易所数据显示， 泓博医药4天3板。该股今日于14时50分封涨停，成交额22.86亿元，换手率 30.48%。金融界App AI线索挖掘：近期 AI医疗概念受到市场关注，相关领域动态频出。摩根大通医疗 健康大会期间，英伟达与礼来宣布将在五年内斥资10亿美元建立联合研究实验室，加速AI药物研发进 程。泓博医药专注于小分子 创新药物研发与生产，业务覆盖药物发现、合成工艺开发及商业化生产等 环节，属于AI医药细分领域，其业务模式与AI药物研发的行业趋势相契合，受到市场关注。 风险提 示：连板股波动剧烈，注意追高风险，理性投资！（注：以上由AI基于交易所等公开数据生成，内容 不构成投资建议。） ...

Group 1 - The core point of the article is the dramatic price fluctuation of the stock "药捷安康-B" after being included in the Hong Kong Stock Connect and index constituent stocks, leading to significant trading volume and volatility [1][3][12] - From September 8 to September 16, the stock price surged nearly 10 times, reaching a peak of 679.5 HKD, which is a 50-fold increase from its IPO price of 13.15 HKD [1][3] - On September 16, the stock experienced a massive drop of 53.73% after a peak increase of 63.73%, highlighting the volatility and risks associated with small-cap stocks in index funds [1][8] Group 2 - Prior to September 8, "药捷安康-B" was a typical small-cap stock with an average daily trading volume of only 16 million HKD, and it had incurred losses of 343 million CNY in 2023 [3][5] - After being included in the Hong Kong Stock Connect, the stock saw a significant influx of capital, with the number of shares held by the Hong Kong Stock Connect increasing from 96,000 to 409,950 shares by September 16, representing 74.67% of the actual circulating shares [5][6] - The stock's price increase was driven by passive funds that needed to adjust their holdings in response to its inclusion in the index, leading to a feedback loop of rising prices and increased demand [7][8] Group 3 - The article discusses the broader trend of index investing, which has gained popularity due to its low cost and transparency compared to active management, with the total net asset value of stock ETFs in Hong Kong reaching 3.53 trillion HKD by September 16 [12][13] - The rapid growth of index funds has been supported by the increasing difficulty for active funds to outperform the market, leading to a shift in investor preference towards ETFs [17][18] - The expansion of index funds is expected to enhance market pricing efficiency and reduce irrational volatility, although it may also lead to concentration in index-weighted stocks, impacting liquidity for other stocks [27][28]

Policy Support - Shenzhen has introduced 32 policy measures to support the entire pharmaceutical and medical device industry chain, focusing on areas such as preclinical research, clinical trials, registration approval, production, and market application [1][2] - The measures emphasize support for emerging technologies and new business models, including "AI+" in pharmaceuticals, biomanufacturing, cell and gene therapy, pet pharmaceuticals, rare disease drugs, and traditional Chinese medicine [1][2] Financial Incentives - The measures provide significant financial rewards for innovative drug development, offering up to 30 million yuan for successful clinical trials of Class 1 innovative drugs [2] - Financial support for pet pharmaceuticals includes rewards of 300,000 yuan, 200,000 yuan, and 100,000 yuan for different categories of new veterinary drugs, with a cap of 500,000 yuan per enterprise annually [2] Clinical Trial Enhancements - Shenzhen aims to establish an international clinical trial center in the Greater Bay Area, optimizing clinical trial processes to reduce internal approval times to within 25 weeks [3] - The measures support the integration of innovative drugs and medical devices, expanding the "Hong Kong-Macau Drug and Device Pass" to include more medical institutions [3] Infrastructure Development - Shenzhen plans to allocate at least 200,000 square meters of industrial land and 1 million square meters of specialized parks annually, focusing on "AI+ pharmaceuticals" and synthetic biology [3] - Key areas like Guangming Science City and Pingshan National Bio-Industry Base will develop an ecosystem combining parks and platforms with public service facilities [3] Talent Acquisition - The measures include a global talent recruitment plan targeting high-level professionals in cell and gene therapy, with a focus on creating a favorable environment for talent development [4] - Innovations in the clinical research talent evaluation system will incorporate research achievements into promotion criteria, alongside housing and education support [4]